Dr. Craig L. Slingluff, University of Virginia, discusses novel approaches to immunotherapy, including adoptive T-cell therapy, personalized cancer vaccines and personalized selection of immune therapies.

Dr. Mario Sznol, Yale School of Medicine, provides a detailed description of the mechanism of action of immunotherapy agents and discusses early data on the use of combination therapies.

Dr. Julie Brahmer, Johns Hopkins University, discusses the use of biomarker testing and mutational burden to select patients for specific immunotherapies in lung cancer, renal cell carcinoma and melanoma.

Dr. Ed Kim from the Levine Cancer Institute reviews the potential advantages and current limitations of blood-based testing for molecular markers using circulating tumor cells and circulating tumor DNA in identifying clinically important mutations.

Dr. Ed Kim from the Levine Cancer Institute in Charlotte, NC summarizes the mechanism of next generation sequencing (NGS), how it can potentially be used, and its limitations in clinical practice today.

Dr. Mario Sznol, Yale School of Medicine, provides an overview of melanoma and its treatment, and discusses current melanoma immunotherapies and other agents under investigation.

Dr. Julie Brahmer, Johns Hopkins University, discusses immunotherapies for NSCLC and SCLC, analyzes the relevant trial data and addresses the unique side effects of these therapies.

Dr. James Gulley, National Cancer Institute, discusses immunotherapies for genitourinary cancers, including recent trial results. He also addresses early data which may indicate that using immunotherapy sooner may benefit patients.

Terrie Schmith, a stage IV melanoma survivor, describes her battle with the disease and her successful treatment with pembrolizumab.

Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.